Costs, quality of life and disease severity in multiple sclerosis: A cross-sectional study in Sweden

European Journal of Neurology

Volumn 8, Issue 1, 2001, Pages 27-35

  Henriksson, F ^a   Fredrikson, S ^b   Masterman, T ^b   Jonsson B ^a  

^a STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cost of illness; EDSS; Multiple sclerosis; Quality of life; Utility

Indexed keywords

BACLOFEN; BETA1A INTERFERON; CARBAMAZEPINE; CITALOPRAM; INTERFERON BETA SERINE; OXYBUTYNIN; TARTARIC ACID; TOLTERODINE;

ADULT; ARTICLE; CORRELATION FUNCTION; COST OF ILLNESS; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PHYSICAL DISABILITY; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; SWEDEN; UTILIZATION REVIEW;

AMBULATORY CARE; CROSS-SECTIONAL STUDIES; DRUG COSTS; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS; QUALITY OF LIFE; REHABILITATION; RETIREMENT; SEVERITY OF ILLNESS INDEX; SWEDEN; TIME FACTORS;

EID: 0035126067     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2001.00169.x     Document Type: Article

References (33)

1. Place of residence determines access to interferon-beta therapy in MS
2. The time trade-off method: Results from a general population study
3. Interferon Beta 1B delays progression of disability in secondary progressive multiple sclerosis: Results of a European multicenter randomised study
4. EuroQol: A new facility for the measurement of health related quality of life
5. Economists, values, and health care reform
6. Multiple sclerosis and other demyelinating diseases
7. The economic cost of multiple sclerosis in Sweden in 1994
8. Cost-of-illness methodology: A guide to assessment practices and procedures
9. Interferon beta 1b is effective in relapsing-remitting multiple sclerosis: Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
10. Intramuscular Interferon Beta 1a for disease progression in relapsing multiple sclerosis
11. Rating neurological impairment in multiple sclerosis and expanded disability status scale (EDSS)
12. FASS. La 3kemedel i Sverige
13. Defining the clinical course of multiple sclerosis: Results of an international survey
14. Health-state utilities in a general population in relation to age, gender and socioeconomic factors
15. Economic evaluation of multiple sclerosis in the UK
16. US and UK health economics: Two disciplines separated by a common language?
17. A cost-utility analysis of interferon beta for multiple sclerosis
18. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
19. Prislista
20. Randomised double-blind placebo-controlled study of interferon β 1a in relapsing/remitting multiple sclerosis
21. Estimating the cost of illness
22. Interferon b in multiple sclerosis. Can we control its costs?
23. Economic costs of illness: Decision making applications and practical considerations
24. A comprehensive assessment of the cost of multiple sclerosis in the United States